Medtronic cuts costs
This article was originally published in The Gray Sheet
Planned elimination of 900 positions is part of an ongoing restructuring effort aimed at saving $125 million annually and is expected to be complete by next April, the firm discloses in a Sept. 5 10-Q filing with the Securities and Exchange Commission. The reductions in force, of which about 350 had been achieved as of July 27, will include early retirements, and voluntary and involuntary separations. The effort, which began earlier this year, includes driving manufacturing efficiencies in the firm's cardiovascular business, downsizing its Physio-Control external defibrillator unit and rebalancing resources in its cardiac rhythm disease management business "in response to current market dynamics," the firm explains (1"The Gray Sheet" Aug. 27, 2007, p. 4)...
You may also be interested in...
Medtronic has trained over 800 surgeons to date on the use of its Prestige artificial cervical disc and will train 200 more each weekend "for the next several weeks," the firm reported Aug. 21 during its fiscal 2008 first quarter earnings call
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.